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SUMMARY
Data were extracted from the case records of UK patients admitted with laboratory-conﬁrmed
inﬂuenza A(H1N1)pdm09. White and non-White patients were characterized by age, sex,
socioeconomic status, pandemic wave and indicators of pre-morbid health status. Logistic
regression examined differences by ethnicity in patient characteristics, care pathway and clinical
outcomes; multivariable models controlled for potential confounders. Whites (n=630) and
non-Whites (n=510) differed by age, socioeconomic status, pandemic wave of admission,
pregnancy, recorded obesity, previous and current smoking, and presence of chronic obstructive
pulmonary disease. After adjustment for a priori confounders non-Whites were less likely to have
received pre-admission antibiotics [adjusted odds ratio (aOR) 0·43, 95% conﬁdence interval (CI)
0·28–0·68, P<0·001) but more likely to receive antiviral drugs as in-patients (aOR 1·53, 95% CI
1·08–2·18, P=0·018). However, there were no signiﬁcant differences by ethnicity in delayed
admission, severity at presentation for admission, or likelihood of severe outcome.
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INTRODUCTION
Ethnicity (commonly regarded as partially synony-
mous with race) may evoke a strong sense of identity,
unity or difference – factors inextricably linked to
health. There are grounds for postulating ethnic
differences in exposure to inﬂuenza virus, suscepti-
bility to infection once exposed, and timely access to
effective treatment [1, 2]. Disparities or inequalities
in inﬂuenza-related outcomes such as pneumonia
can be observed for some minority groups [3, 4]. A
cross-sectional survey of 1479 US households (with
oversampling of minority groups) suggests Spanish-
speaking Hispanics were at increased risk of presumed
inﬂuenza A(H1N1)pdm09 exposure, but reduced risk
of related complications; Blacks were more susceptible
to self-reported complications [5]. Analysis of US
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Centers for Disease Control and Prevention (CDC)
surveillance data collected during the 2009 pandemic
found no ethnic/racial disparities in healthcare-seeking
behaviour for inﬂuenza-like illness, but higher hospi-
talization rates in minority groups and higher paedia-
tric mortality in Hispanics [6]. A Canadian study of
413 laboratory-conﬁrmed inﬂuenza A(H1N1)pdm09
cases compared to test-negative community controls re-
ports over-representation of ethnic minority cases [7].
These seemingly consistent patterns are concerning
and while the effect of ethnicity may have plausible
biological underpinnings it is also strongly linked to
social context, requiring that international compari-
sons be made with caution. In the UK, based on a
total of 70 paediatric deaths related to inﬂuenza
A(H1N1)pdm09 (including those in the community),
age-standardized mortality rates for Bangladeshi chil-
dren [47 deaths per million population (dpm), 95%
conﬁdence interval (CI) 17–103] and Pakistani chil-
dren (36 dpm, 95% CI 18–64) were found to be higher
than for White British children (4 dpm, 95% CI 3–6)
[8]. Where such inequitable outcomes are suggested,
our professional and moral obligations to redress
them, reduce disparities in access to healthcare and
improve patients’ experiences can only be effected
through measuring all relevant dimensions – one of
which is ethnicity [9].
During the 2009 inﬂuenza pandemic the Depart-
ment of Health (England) collected data on risk
factors, including ethnicity, via the Inﬂuenza Clinical
Information Network (FLU-CIN) programme [10].
Analysis of the ﬁrst-wave FLU-CIN cohort (May–
September 2009) indicated that ethnic minorities
were over-represented among those admitted to hospi-
tal [10]; this was less pronounced in the second wave
[11], but nevertheless raises the possibility of system-
atic differences in care. Figures 1 and 2, respectively,
compare the ethnic composition and age proﬁle of
the FLU-CIN cohort with that of the UK general
population and persons admitted to UK hospitals
with acute respiratory infection (ARI) in the immedi-
ate pre-pandemic period winter season. To gain in-
sight into these striking observations we report an
analysis of FLU-CIN enhanced surveillance data
over both pandemic waves, investigating possible
ethnic differences in care pathway and clinical out-
come in patients hospitalized with laboratory-
conﬁrmed inﬂuenza A(H1N1)pdm09 in the UK.
METHODS
As previously described, trained nursing staff ex-
tracted data from the case records of patients hospita-
lized for laboratory-conﬁrmed inﬂuenza A(H1N1)
pdm09, without other selection criteria [10]. These in-
cluded ethnicity as recorded in case notes, according
to the Ofﬁce for National Statistics Census classiﬁca-
tion (www.statistics.gov.uk). This ofﬁcial UK system
of classiﬁcation can be regarded as equivalent to racial
group in the majority of cases.
(a) (b)
Fig. 1. FLU-CIN population pyramids for ethnic composition* with comparison to (a) the UK general population† and
(b) admissions to UK hospitals with acute respiratory infection (ARI) in the pre-pandemic period‡. [* 1140 cases; excludes
380 cases (25%) missing ethnicity data. † Demographic data on ethnicity derived from Ofﬁce of National Statistics Census
(2001) and General Register Ofﬁce for Scotland and Northern Ireland Statistics and Research Agency (2001). ‡ Hospital
Episodes Statistics data on primary discharge codes relating to possible inﬂuenza admissions (J06, J10, J11, J13–22)
during November 2008–March 2009.]
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We conceptualized a patient care pathway com-
mencing with pre-admission care in the community;
primary healthcare access indicators comprised use
of self-medication, general practitioner (GP) consul-
tation and receipt of pre-admission antibiotics or
antivirals. Secondary healthcare access indicators
comprised two proxy measures of access to hospital:
admission delay of 54 days from illness onset and
illness severity at presentation for admission. The
pathway concluded with indicators corresponding to
in-patient care, these being receipt of in-patient anti-
biotics or antivirals. The clinical outcomes of interest
were length of stay in hospital, admission to high-
dependency or critical-care facilities and death. A
number of covariates related to this pathway and clini-
cal outcomes were identiﬁed and deﬁned as follows.
Socioeconomic status was estimated from postcode
of residence using the English Index of Multiple De-
privation (IMD) 2007, a composite area-based
measure of deprivation that takes account of income,
employment, health status and disability, education
and skills, access to services, living environment and
area-level crime [12]. IMDscoreswere grouped to facili-
tate comparison by ‘most afﬂuent’ (IMD 414·999),
‘afﬂuent’ (IMD 15–29·999), ‘deprived’ (IMD 30–
44·999) and ‘most deprived’ (IMD 545) status.
National surveillance data determined assignment
to the ﬁrst (pre-September 2009) or second pandemic
wave [13]. The National Pandemic Flu Service
(NPFS) antiviral distribution system began operation
during the ﬁrst wave on 23 July 2009 [14]; we created
a variable representing availability of the NPFS in
order to model the effect of access to the service on
antiviral availability.
Baseline health status incorporated a measure of the
presence of comorbidities, the Charlson Comorbidity
Index (CCI); the weighted CCI scores were cate-
gorized as ‘0’ (no comorbidities), 1–2, 3–5 and >5
[15, 16].
Early treatment with antivirals was deﬁned as re-
ceipt within 2 days of symptom onset; late treatment
was deﬁned as receipt >2 days after onset of
symptoms.
Delayed admission was deﬁned by pandemic inﬂu-
enza experts on the FLU-CIN Steering Group as
admission delay of 54 days following onset of
symptoms.
Illness severity at presentation was assessed
using the community assessment tools (CATs) for
triage (seven criteria as outlined in Supplementary
Table S1), as recommended for use during a severe
pandemic by the Department of Health, England
[17, 18].
Admission for 52 days was regarded as prolonged
and thus a proxy measure for a more severe illness
during hospitalization.
Type of admission was coded as level 0: patients
whose care needs can be met through normal ward
care; level 1: patients at risk of deteriorating or re-
cently relocated from higher levels of care whose
needs can be met on an acute ward with additional ad-
vice and support from the critical care team; level 2:
patients requiring more detailed observation or inter-
vention including support for a single failing organ
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Fig. 2. FLU-CIN population pyramids for age by broad ethnic group* with comparison to (a) the UK general
population† and (b) admissions to UK hospitals with acute respiratory infection in the pre-pandemic period‡. [* 1140
cases; excludes 380 cases (25%) missing ethnicity data. † Demographic data on age distribution derived from Ofﬁce of
National Statistics 2009 mid-year population estimates (www.statistics.gov.uk). ‡ Hospital Episodes Statistics data on
primary discharge codes relating to possible inﬂuenza admissions (J06, J10, J11, J13–22) during November 2008–March
2009.]
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system and those ‘stepping down’ from higher levels of
care – high dependency unit (HDU); level 3: patients
requiring advanced respiratory support alone or
basic respiratory support together with support of at
least two organ systems. This includes all complex
patients requiring support for multi-organ failure –
intensive care unit (ICU).
Univariate logistic regression analyses (Table 1)
examined unadjusted associations between ethnicity
(White or non-White) and patient characteristics at
the point of admission to hospital with inﬂuenza
A(H1N1)pdm09. A multivariable logistic regression
model (Table 2) was used to adjust care pathway and
clinical outcome indicators for potential confounders
including age, sex, socioeconomic status, pandemic
wave and (for outcomes related to in-patient care and
mortality) delayed admission and severity at presen-
tation for admission (model A). An alternative concep-
tual model (model B) further adjusted for variables
found to be signiﬁcantly maldistributed according
to ethnicity (recorded obesity, current smoking and
chronic obstructive pulmonary disease; pregnancy was
excluded owing to the inclusion of males in the cohort).
Ethical standards
The Ethics and Conﬁdentiality Committee (ECC)
of the National Information Governance Board
for Health and Social Care (NIGB) gave permission
for the collection of patient-identiﬁable data for
FLU-CIN in May 2009, noting the urgency and wider
public interest of this surveillance study. Section 251
approval was not sought for exemption from gaining
informed consent; provision of patient information
in sentinel centres was stipulated. The authors assert
that all procedures contributing to this work comply
with the ethical standards of the relevant national
and institutional committees on human experimen-
tation and with the Helsinki Declaration of 1975, as
revised in 2008.
RESULTS
Of 1520 admissions in the FLU-CIN cohort [11],
1140 (75·0%) had ethnicity recorded (missing data
n=380, 25·0%). A summary of patients’ character-
istics is given in Table 1. Non-White patients con-
stituted almost half (n=510, 44·7%) of the study
population, the largest subgroup being Asian or
Asian British (n=249, 21·8%). Similar data for
major non-White ethnic subgroups are provided in
Supplementary Table S2.
Table 2 presents unadjusted (crude) odds and
adjusted odds for both logistic regression models
comparing non-Whites to Whites; these are grouped
by care pathway and clinical outcome indicators.
Similar data for major non-White ethnic subgroups
are provided in Supplementary Table S3.
In respect of access to primary healthcare non-
Whites were less likely to receive pre-admission anti-
biotics [model A, adjusted aOR (aOR) 0·43, 95% CI
0·28–0·68, P<0·001), but no more or less likely to re-
ceive pre-admission antivirals (aOR 0·86, 95% CI
0·51–1·43, P=0·554). Substituting the a priori variable
for pandemic wave in model A for a variable rep-
resenting access to the NPFS did not signiﬁcantly
alter the likelihood of receiving pre-admission anti-
virals by ethnicity (aOR 0·89, 95% CI 0·54–1·47,
P=0·662). Furthermore, there was no signiﬁcant
difference in the interval between date of symptom
onset and date of antiviral receipt (i.e. early vs. late
treatment), by ethnicity (OR 1·27, 95% CI 0·90–
1·77, P=0·169). Insufﬁcient data on pandemic vacci-
nation were available for inclusion in multivariable
models (missing data, 73·5%) and 750 cases presented
for admission prior to the availability of vaccine.
As a proxy measure of access to secondary health-
care, crude odds indicated non-Whites were less likely
to experience an admission delay of 54 days after
symptom onset, but after adjustment this difference
was not statistically signiﬁcant. Likewise, no signiﬁ-
cant difference in illness severity at presentation for ad-
mission was observed between Whites and non-Whites
(Table 2).
During the in-patient phase of the pathway non-
White ethnic groups were more likely to receive anti-
viral drugs (model A: aOR 1·53, 95% CI 1·08–2·18,
P=0·018). A higher likelihood of non-Whites receiv-
ing antibiotics as in-patients became non-signiﬁcant
after adjustment.
In terms of clinical outcomes no signiﬁcant differ-
ences were found for in-patient stays of 52 days
(indicating protracted illness). Crude odds indicated
non-Whites were less likely to require high-dependency
or intensive-care unit admission; however, after adjust-
ment this difference was not statistically signiﬁcant.
No signiﬁcant differences were found for mortality.
DISCUSSION
Poorer inﬂuenza-related outcomes among indigenous
peoples have been observed in Alaska, Sierra Leone
[19], Australia [20] and New Zealand [4, 21] during
4 G. A. Nyland and others
Table 1. FLU-CIN patients’ characteristics at the point of admission to hospital with inﬂuenza A(H1N1)pdm09 in
the UK by broad ethnic group (n=1140)
Characteristics
White
(N=630), n (%)
Non-White
(N=510), n (%)
Crude OR
(95% CI) P value
Ethnic grouping, N/n (%)
White 630/1140 (55·3)
Mixed 11/1140 (1·0)
Asian or Asian British 249/1140 (21·8)
Black or Black British 129/1140 (11·3)
Chinese and other 121/1140 (10·6)
Sex
Male 291 (46·2) 238 (46·7) 1·00
Female 339 (53·8) 272 (53·3) 0·98 (0·78–1·24) 0·873
Age (years)
<1 50 (7·9) 40 (7·8) 1·00 P trend=0·001
1–4 55 (8·7) 53 (10·4) 1·20 (0·69–2·11)
5–15 79 (12·5) 89 (17·5) 1·41 (0·84–2·36)
16–24 107 (17·0) 88 (17·3) 1·03 (0·62–1·70)
25–34 88 (14·0) 87 (17·1) 1·24 (0·74–2·06)
35–44 82 (13·0) 62 (12·2) 0·95 (0·56–1·61)
45–54 77 (12·2) 47 (9·2) 0·76 (0·44–1·32)
55–64 52 (8·3) 25 (4·9) 0·60 (0·32–1·13)
65–74 27 (4·3) 14 (2·8) 0·65 (0·30–1·40)
>75 13 (2·1) 5 (1·0) 0·48 (0·16–1·46)
Socioeconomic status (IMD group)
Most afﬂuent (IMD 414·999) 92 (14·6) 35 (6·9) 1·00 P trend <0·001
Afﬂuent (IMD 15–29·999) 126 (20·0) 113 (22·2) 2·36 (1·48–3·75)
Deprived (IMD 30–44·999) 59 (9·4) 134 (26·3) 5·97 (3·64–9·80)
Most deprived (IMD 545) 91 (14·4) 143 (28·0) 4·13 (2·58–6·61)
Missing data 262 (41·6) 85 (16·7)
Pandemic wave
First wave 180 (28·6) 337 (66·1) 1·00
Second wave 450 (71·4) 173 (33·9) 0·21 (0·16–0·26) <0·001
Health status
Current pregnancy* 27 (16·0) 39 (26·0) 1·85 (1·07–3·20) 0·029
Recorded obesity† 26 (4·1) 10 (2·0) 0·46 (0·22–0·97) 0·042
Current smoker 120 (19·1) 44 (8·6) 0·45 (0·31–0·66) <0·001
Missing data 220 (34·9) 229 (44·9)
Ever smoked 171 (27·1) 64 (12·5) 0·41 (0·29–0·58) <0·001
Missing data 220 (34·9) 229 (44·9)
Asthma diagnosis 158 (25·1) 137 (26·9) 1·10 (0·84–1·43) 0·494
COPD diagnosis 49 (7·8) 8 (1·6) 0·19 (0·09–0·40) <0·001
Other lung disease 15 (2·4) 13 (2·6) 1·07 (0·51–2·27) 0·855
No comorbidity, CCI 0 322 (51·1) 299 (58·6) 1·00 P trend=0·052
CCI 1–2 272 (43·2) 181 (35·5) 0·72 (0·56–0·92)
CCI 3–5 35 (5·6) 28 (5·5) 0·86 (0·51–1·45)
CCI >5 1 (0·2) 2 (0·4) 2·15 (0·19–23·88)
IMD, English Index of Multiple Deprivation (2007); COPD, chronic obstructive pulmonary disease; CCI, Charlson
Comorbidity Index; OR, odds ratio; CI, conﬁdence interval.
Percentages may not add up to 100 due to rounding; statistically signiﬁcant results shown in bold (P<0·05).
* Expressed as a percentage of women of childbearing age (14–44 years).
† Physician-recorded in case notes.
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Table 2. Care pathway and clinical outcomes for patients admitted with inﬂuenza A(H1N1)pdm09 in the UK by broad ethnic group (n=1140)
Variable
White
(N=630) n (%)
Non-White
(N=510) n (%)
Crude OR (95% CI);
P value
Adjusted OR (95% CI);
P value (model A)
Adjusted OR (95% CI);
P value (model B)
Primary healthcare access indicators
Self-medication 49 (7·8) 39 (7·7) 0·98 (0·63–1·52); 0·934 1·33 (0·75–2·35); 0·327 1·28 (0·72–2·28); 0·402
GP consultation 180 (28·6) 139 (27·3) 0·94 (0·72–1·22); 0·622 0·82 (0·58–1·15); 0·255 0·84 (0·59–1·19); 0·322
Missing data 296 (47·0) 227 (44·5)
Pre-admission antibiotic 142 (22·5) 54 (10·6) 0·41 (0·29–0·57); <0·001 0·43 (0·28–0·68); <0·001 0·42 (0·27–0·67); <0·001
Pre-admission antiviral 68 (10·8) 51 (10·0) 0·92 (0·63–1·35); 0·663 0·86 (0·51–1·43); 0·554 0·81(0·48–1·35); 0·412
Secondary healthcare access indicators
Admission delay54 days 133 (21·1) 95 (18·6) 0·65 (0·48–0·88); 0·006 0·73 (0·49–1·09); 0·119 0·71 (0·47–1·07); 0·103
Missing data 198 (31·4) 86 (16·8)
Severity at presentation† 468 (74·3) 367 (72·0) 0·89 (0·68–1·16); 0·378 1·10 (0·79 −1·54); 0·576 1·16 (0·83–1·64); 0·387
In-patient care indicators
In-patient antibiotic 513 (81·4) 440 (86·3) 1·43 (1·04–1·98); 0·029 1·37* (0·84–2·22); 0·204 1·46 (0·94–2·26); 0·095
In-patient antiviral 452 (71·8) 398 (78·0) 1·40 (1·07–1·84); 0·015 1·53* (1·08–2·18); 0·018 1·66 (1·15–2·39); 0·006
Clinical outcomes
Length of stay52 days 427 (67·8) 357 (70·0) 0·82 (0·61–1·11); 0·195 1·04* (0·71–1·53); 0·840 1·11 (0·75–1·62); 0·607
Missing data 93 (14·8) 41 (8·0)
Level 2 or 3 admission‡ 109 (17·3) 66 (12·9) 0·71 (0·51–0·99); 0·043 1·19* (0·74–1·92); 0·478 1·25 (0·77–2·03); 0·368
Death 35 (5·6) 20 (3·9) 0·69 (0·40–1·22); 0·203 0·80* (0·35–1·82); 0·602 0·77 (0·33–1·80); 0·550
GP, General practitioner; OR, odds ratio; CI, conﬁdence interval; adjusted OR (model A), adjusted for a priori confounders of age, sex, English Index of Multiple Deprivation
(IMD 2007) score derived from postal code of residence and pandemic wave; adjusted OR (model B), adjusted for age, sex, IMD 2007 score, pandemic wave, recorded obesity,
current smoking and chronic obstructive pulmonary disease.
* Adjusted for admission delay 54 days and severity at presentation for admission.
†One or more clinical indicators of severe disease at triage (see text).
‡Requiring high-dependency unit or critical care unit.
Percentages may not add up to 100 due to rounding; statistically signiﬁcant results shown in bold (P<0·05).
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previous inﬂuenza pandemics. Similar observations
were made among Canadian First Nations communi-
ties [22] and in Alaska [23] during the 2009 pandemic.
By contrast, the UK’s ethnic minority population
is non-indigenous, and has resulted largely from im-
migration over the last 60 years. However, larger non-
indigenous ethnic groups in North America were also
reported to experience adverse outcomes during the
2009 pandemic [7, 24]. We can therefore infer complex
relationships between biological and social factors
that shape observed differences by ethnicity. For this
reason it may not be prudent to generalize ﬁndings
from one country to the ethnic minorities of another.
Measuring ethnicity accurately is a further chal-
lenge, and the value of aggregate ethnicity data in epi-
demiological research is contentious. Individuals may
deﬁne their ethnicity in terms of parentage, race,
cultural heritage or afﬁliation (for example). As race,
skin colour, country of origin or cultural afﬁliation
are not necessarily synonymous with a particular
ethnic risk proﬁle, there is some potential for misclas-
siﬁcation bias. Broad groupings such as ‘White’ or
‘non-White’ encompass much diversity (in social,
cultural, religious, or genetic traits for example) and
sensitivities to being so ‘lumped together’ must be ac-
knowledged. Such aggregation has pragmatic value
(overcoming low numbers encountered with more
granular ethnic groupings, where annual data cannot
be pooled [25]), precedent (usage in routine statistics)
and utility in hypothesis generation to scrutinize ac-
cess inequalities. Unfortunately, although aggregation
does improve statistical conﬁdence, it also increases
heterogeneity. As 45% of the FLU-CIN cohort was
non-White, in order to balance these considerations
we also compared major non-White ethnic subgroups
to White groups (Supplementary Tables S2 and S3).
The pattern of over-representation of non-Whites
in both the FLU-CIN cohort and the population ad-
mitted with ARI in 2008–2009 is broadly consistent
(Fig. 1). ARI offers a valid comparison given that ad-
mission thresholds by ethnicity are unlikely to differ be-
tween presentation with pandemic inﬂuenza or with
clinically indistinguishable respiratory virus infections
(including seasonal inﬂuenza) in the previous winter
season. It is equally important to note the highly sig-
niﬁcant reversal in proportion of Whites to non-
Whites in FLU-CIN cases between the ﬁrst and
second pandemic waves (Table 1). Mapping of cases
by postcode of residence according to pandemic
wave (Supplementary Fig. S1) highlighted urban clus-
tering of admissions, particularly around London and
the West Midlands during the ﬁrst wave, spreading to
the East Midlands and Northwest (with less ethnically
diverse populations) during the second wave. These
data suggest that the initial predominance of non-
White patients in the ﬁrst pandemic wave and some
degree of reversal as pandemic activity dispersed in
the second wave was mainly attributable to place of
residence, rather than inherent predisposition. This ex-
planation would not exclude the possibility that vul-
nerable members of ethnic minority communities
experienced higher risk of exposure to inﬂuenza
A(H1N1)pdm09 prior to availability of pandemic vac-
cine, which may still indicate the need for more effec-
tive promotion of measures such as hand hygiene
advice and social distancing during the initial pan-
demic period.
While non-Whites were less likely to have received
pre-admission antibiotics, there was no compensatory
increase in the likelihood of receiving pre-admission
antivirals. If antibiotic prescriptions do reﬂect access
to primary healthcare then use of fewer antibiotics
for non-Whites might indicate a reduced propensity
among minority groups to seek care, culturally or edu-
cationally mediated beliefs about the value of antibio-
tics, or typical attitudes to risk [1, 2]. Alternatively, it
might indicate antibiotic prescribing practices that dis-
criminate against ethnic minorities or are inappropri-
ately responsive to demand from White patients. We
note that Whites and non-Whites were equally likely
to self-medicate; access barriers to community phar-
macies may be lower. However, similar access to GP
consultations and to pre-admission antivirals between
Whites and non-Whites would argue against wider
access barriers.
For access to secondary healthcare we found no
difference between Whites and non-Whites in terms
of admission delay or disease severity at presentation
for admission (Table 2 and Supplementary
Table S1), suggesting that differences in pre-hospital
antibiotic receipt by ethnicity did not impact on
timing of, or severity at admission. FLU-CIN was
not conﬁgured to report inﬂuenza A(H1N1)pdm09
hospitalization rates by ethnicity for hospital catch-
ment areas, thus our data cannot comment on excess
rates observed among minority groups measured else-
where [6, 22, 24, 26, 27].
Given the absence of any difference between Whites
and non-Whites at the point of admission, it is some-
what surprising that the latter were more likely to
have received antiviral drugs as in-patients (Table 2).
This is not explained by non-Whites presenting
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disproportionately as ﬁrst-wave cases, when prescrib-
ing of antivirals could have been more cautious. The
difference by ethnicity was not signiﬁcant for ﬁrst-
wave admissions, where 74·4% of Whites (n=134)
and 79·0% of non-Whites (n=266) received in-patient
antivirals (model A: aOR 1·23, 95% CI 0·73–2·07, P=
0·434). The difference was, however, signiﬁcant
for second-wave admissions, where 70·7% of Whites
(n=318) and 76·3% of non-Whites (n=132) received
in-patient antivirals (model A: aOR 1·76, 95% CI
1·05–2·94, P=0·033).
Our study did not ﬁnd any evidence that small dif-
ferences in care pathway resulted in signiﬁcant differ-
ences in clinical outcome by ethnicity. Non-Whites
were not disadvantaged as judged by mortality or
level 2/3 admission using either our a priori or concep-
tual model to adjust for potential confounding. Our
results juxtapose the Canadian experience where in-
digenous First Nations ethnicity was an independent
risk factor for ICU admission [28]. The UK non-
White population may be regarded as non-indigenous,
yet mortality in New Zealand was reported as ‘signiﬁc-
antly’ higher in non-indigenous Paciﬁc Peoples
(infection rate-adjusted rate ratio 3·28, 95% CI
1·44–7·49, P value not stated) [27]. This may suggest
that indigenous ethnic status, while being partly gen-
etic/biological (perhaps modulating illness severity or
response to therapy), is being confounded by other
factors. Quinn and colleagues postulate the operation
of differential risks of inﬂuenza exposure, suscepti-
bility and healthcare access that worsen existing
inequities [5], which may themselves be independently
associated with ethnicity/race or socioeconomic status
or both. In their review of 4874 inﬂuenza A(H1N1)
pdm09-related discharges in Massachusetts, Placzek
& Madoff found both minority ethnic/racial group
and lower socioeconomic status predicted ICU stay
[24]. Compared to non-Hispanic Whites, Hispanics
were less likely to be admitted to an ICU (aOR
0·52, 95% CI 0·32–0·86, P<0·05); of patients admit-
ted to ICUs, 63% of Hispanics, 43% of
non-Hispanic Blacks and only 13% of non-Hispanic
Whites were among the least afﬂuent socioeconomic
group [24]. Although the authors were unable to
measure differential access to healthcare, differences
in risk perception, healthcare reform, cultural or lan-
guage barriers are mooted as possible contributors.
Taken together with our own ﬁndings, these observa-
tions likely reﬂect a complex and confounded relation-
ship between clinical outcomes for inﬂuenza A(H1N1)
pdm09, ethnicity and social disadvantage [29].
Our study does not provide compelling evidence
of important disparities in ‘downstream’ access to
primary or secondary care treatment for inﬂuenza
A(H1N1)pdm09 in the UK. Our ﬁndings do, however,
mirror the over-representation of non-Whites among
A(H1N1)pdm09-related hospital admissions reported
elsewhere. This might reﬂect a difference in sus-
ceptibility to infection, either biological or by means
of difference in uptake of the ‘midstream’ intervention
of vaccination. Our study refutes vaccination as an
explanation, given that over-representation preceded
availability of pandemic vaccine. Over-representation
of non-Whites most likely relates to ‘upstream’ factors
that determine exposure to the inﬂuenza virus. We
provide evidence that geography played a key role
in determining this pattern, which is also the basis of
measuring socioeconomic status in the UK. Co-
related upstream factors include population density,
crowded living conditions, reliance on public trans-
port, occupational group, acceptability of social dis-
tancing and use of communal childcare facilities
[1, 2]. The challenge for future research is to unpick
the contribution of such factors and to determine
whether variation is attributable to ethnicity, socio-
economic status or both.
CONCLUSIONS
Ethnicity was not a signiﬁcant predictor of inequities
or disparities in care pathway or of clinical outcomes
for patients hospitalized with inﬂuenza A(H1N1)
pdm09 in the UK. We did not ﬁnd any evidence
that small differences in care pathway resulted in sig-
niﬁcant differences in clinical outcome by ethnicity.
SUPPLEMENTARY MATERIAL
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